Brief: Skye Bioscience Completes Enrollment of Phase 2a Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
26/02/2024 12:07
Feb 26 (Reuters) - Skye Bioscience Inc SKYE.PK :
* SKYE BIOSCIENCE COMPLETES ENROLLMENT OF PHASE 2A CLINICAL
TRIAL
OF SBI-100 OPHTHALMIC EMULSION IN GLAUCOMA AND OCULAR
HYPERTENSION
Source text for Eikon: ID:nGNXZRWwj
Further company coverage: SKYE.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsRCS - Redx Pharma Limited - Redx to Present Poster on RXC008 at UEG Week
RCS - Redx Pharma Limited - Redx Announces ROCKETEER Phase 2 Trial for RXC008
Brief: Skye Bioscience Says John Sharp Resigns As CFO - SEC Filing
Brief: Skye Bioscience - Enters $22 Million Securities Purchase Agreement With Redmile Biopharma Investments Iii - SEC Filing
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM